Cargando…
Intranasal immunization with an RBD-hemagglutinin fusion protein harnesses preexisting immunity to enhance antigen-specific responses
Intranasal vaccines are anticipated to be powerful tools for combating many infectious diseases, including SARS-CoV-2, because they induce not only systemic immunity but also mucosal immunity at the site of initial infection. However, they are generally inefficient in inducing an antigen-specific im...
Autores principales: | Kawai, Atsushi, Tokunoh, Nagisa, Kawahara, Eigo, Tamiya, Shigeyuki, Okamura, Shinya, Ono, Chikako, Anindita, Jessica, Tanaka, Hiroki, Akita, Hidetaka, Yamasaki, Sho, Kunisawa, Jun, Okamoto, Toru, Matsuura, Yoshiharu, Hirai, Toshiro, Yoshioka, Yasuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688985/ https://www.ncbi.nlm.nih.gov/pubmed/38038133 http://dx.doi.org/10.1172/JCI166827 |
Ejemplares similares
-
A nasal vaccine with inactivated whole-virion elicits protective mucosal immunity against SARS-CoV-2 in mice
por: Tokunoh, Nagisa, et al.
Publicado: (2023) -
Intranasal Administration of RBD Nanoparticles Confers Induction of Mucosal and Systemic Immunity against SARS-CoV-2
por: Jearanaiwitayakul, Tuksin, et al.
Publicado: (2021) -
Heterosubtypic Antiviral Activity of Hemagglutinin-Specific Antibodies Induced by Intranasal Immunization with Inactivated Influenza Viruses in Mice
por: Muramatsu, Mieko, et al.
Publicado: (2013) -
Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse
por: Du, Yingying, et al.
Publicado: (2021) -
COVID-19 in Africa: preexisting immunity and HIV
por: Snyman, Jumari, et al.
Publicado: (2021)